NASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Forecast, Price & News $1.27 -0.02 (-1.17%) (As of 01:44 PM ET) Add Compare Share Share Today's Range$1.21▼$1.4350-Day Range$1.14▼$1.8152-Week Range$1.11▼$6.01Volume2.09 million shsAverage Volume2.64 million shsMarket Capitalization$145.24 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Karyopharm Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside422.9% Upside$6.67 Price TargetShort InterestBearish13.15% of Shares Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment-0.77Based on 2 Articles This WeekInsider TradingAcquiring Shares$50,191 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.10) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector576th out of 963 stocksPharmaceutical Preparations Industry257th out of 451 stocks 3.3 Analyst's Opinion Consensus RatingKaryopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.67, Karyopharm Therapeutics has a forecasted upside of 422.9% from its current price of $1.28.Amount of Analyst CoverageKaryopharm Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.15% of the outstanding shares of Karyopharm Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Karyopharm Therapeutics has recently increased by 2.24%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKaryopharm Therapeutics has received a 71.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Other cancer medication", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Karyopharm Therapeutics is -1.11. Previous Next 1.2 News and Social Media Coverage News SentimentKaryopharm Therapeutics has a news sentiment score of -0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for KPTI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have bought 20.79% more of their company's stock than they have sold. Specifically, they have bought $50,191.00 in company stock and sold $41,551.00 in company stock.Percentage Held by InsidersOnly 3.32% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions70.47% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($1.10) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Karyopharm Therapeutics (NASDAQ:KPTI) StockKaryopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.Read More KPTI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KPTI Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comKaryopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual MeetingsSeptember 1, 2023 | finance.yahoo.comKaryopharm Appoints Zhen Su, MD, MBA to its Board of DirectorsSeptember 27, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 21, 2023 | msn.comKaryopharm Therapeutics: Seeking Upside Potential But Catalysts Too Far AwayAugust 4, 2023 | msn.comPiper Sandler Maintains Karyopharm Therapeutics (KPTI) Overweight RecommendationAugust 3, 2023 | benzinga.com6 Analysts Have This to Say About Karyopharm TherapeuticsAugust 3, 2023 | finance.yahoo.comDozens more biotech jobs axed as two firms make cutsAugust 3, 2023 | markets.businessinsider.comKaryopharm Therapeutics (KPTI) Gets a Buy from BarclaysSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 3, 2023 | finance.yahoo.comKaryopharm Therapeutics (KPTI) Q2 2023 Earnings Call TranscriptAugust 2, 2023 | markets.businessinsider.comKaryopharm Therapeutics Inc. Q2 Loss decreases, beats estimatesAugust 2, 2023 | finance.yahoo.comKaryopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressJuly 27, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Gossamer Bio (GOSS), Karyopharm Therapeutics (KPTI) and Tarsus Pharmaceuticals (TARS)July 27, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Karyopharm Therapeutics (KPTI)July 27, 2023 | msn.comWedbush Maintains Karyopharm Therapeutics (KPTI) Neutral RecommendationJuly 27, 2023 | finance.yahoo.comKaryopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial CancerJuly 27, 2023 | finance.yahoo.comKaryopharm to Report Second Quarter 2023 Financial Results on August 2, 2023July 19, 2023 | finance.yahoo.comKaryopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25thJuly 18, 2023 | theglobeandmail.comHealthcare Stock Bid Up Following FDA Fast TrackJuly 18, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Karyopharm TherapeuticsJuly 17, 2023 | finance.yahoo.comKaryopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of MyelofibrosisJuly 10, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Karyopharm Therapeutics (KPTI)July 5, 2023 | finance.yahoo.comAll You Need to Know About Karyopharm Therapeutics (KPTI) Rating Upgrade to BuyJune 28, 2023 | finance.yahoo.comKaryopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve MyelofibrosisJune 8, 2023 | finance.yahoo.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) is favoured by institutional owners who hold 74% of the companyJune 7, 2023 | markets.businessinsider.comSVB Securities Sticks to Their Hold Rating for Karyopharm Therapeutics (KPTI)May 29, 2023 | markets.businessinsider.comSVB Securities Remains a Hold on Karyopharm Therapeutics (KPTI)See More Headlines Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Company Calendar Last Earnings8/02/2023Today9/27/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KPTI CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees385Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.67 High Stock Price Forecast$10.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+424.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-165,290,000.00 Net Margins-96.97% Pretax Margin-96.77% Return on EquityN/A Return on Assets-46.69% Debt Debt-to-Equity RatioN/A Current Ratio4.94 Quick Ratio4.88 Sales & Book Value Annual Sales$157.07 million Price / Sales0.92 Cash FlowN/A Price / Cash FlowN/A Book Value($0.15) per share Price / Book-8.47Miscellaneous Outstanding Shares114,360,000Free Float110,558,000Market Cap$145.24 million OptionableOptionable Beta-0.01 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Richard A. Paulson M.B.A. (Age 56)Pres, CEO & Director Comp: $1.36MDr. Sharon Shacham M.B.A. (Age 53)Ph.D., Co-Founder & Chairman of Scientific Advisory Board Comp: $1.4MMr. Michael P. Mason CPA (Age 48)M.B.A., Exec. VP, CFO & Treasurer Comp: $681.59kMr. Michael J. Mano J.D. (Age 46)Sr. VP, Gen. Counsel & Sec. Comp: $625.08kMs. Sohanya Cheng M.B.A. (Age 40)Exec. VP & Chief Commercial Officer Comp: $664.3kMr. Stuart PoultonExec. VP & Chief Devel. OfficerDr. Mansoor Raza Mirza M.D. (Age 62)Clinical Consultant, Member of Scientific Advisory Board & Independent Director Comp: $150kMr. Cameron Peters (Age 63)VP of Fin., Assistant Treasurer & Principal Accounting Officer Ms. Elhan Webb C.F.A.Sr. VP of Investor RelationsMr. James Accumanno J.D.Chief Compliance OfficerMore ExecutivesKey CompetitorsRani TherapeuticsNASDAQ:RANICapricor TherapeuticsNASDAQ:CAPRESSA PharmaNASDAQ:EPIXAssertioNASDAQ:ASRTPrelude TherapeuticsNASDAQ:PRLDView All CompetitorsInsiders & InstitutionsGaren G BohlinBought 41,140 shares on 9/12/2023Total: $50,190.80 ($1.22/share)Michael MasonSold 6,913 sharesTotal: $9,194.29 ($1.33/share)Sohanya Roshan ChengSold 7,415 sharesTotal: $9,861.95 ($1.33/share)Michael ManoSold 3,888 sharesTotal: $5,171.04 ($1.33/share)Wolverine Trading LLCBought 11,500 shares on 8/23/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions KPTI Stock - Frequently Asked Questions Should I buy or sell Karyopharm Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KPTI shares. View KPTI analyst ratings or view top-rated stocks. What is Karyopharm Therapeutics' stock price forecast for 2023? 5 brokerages have issued 1 year target prices for Karyopharm Therapeutics' shares. Their KPTI share price forecasts range from $4.00 to $10.00. On average, they predict the company's stock price to reach $6.67 in the next year. This suggests a possible upside of 424.9% from the stock's current price. View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts. How have KPTI shares performed in 2023? Karyopharm Therapeutics' stock was trading at $3.40 at the beginning of the year. Since then, KPTI stock has decreased by 62.6% and is now trading at $1.27. View the best growth stocks for 2023 here. When is Karyopharm Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our KPTI earnings forecast. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its earnings results on Wednesday, August, 2nd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.05. The business earned $37.58 million during the quarter, compared to analyst estimates of $36.23 million. What ETF holds Karyopharm Therapeutics' stock ? iShares Genomics Immunology and Healthcare ETF holds 391,728 shares of KPTI stock, representing 0.49% of its portfolio. What guidance has Karyopharm Therapeutics issued on next quarter's earnings? Karyopharm Therapeutics issued an update on its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $145.00 million-$160.00 million, compared to the consensus revenue estimate of $150.34 million. What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO? 31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY). What is Karyopharm Therapeutics' stock symbol? Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI." Who are Karyopharm Therapeutics' major shareholders? Karyopharm Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.09%), Marshall Wace LLP (2.14%), ExodusPoint Capital Management LP (2.08%), State Street Corp (1.93%), Geode Capital Management LLC (1.87%) and Goldman Sachs Group Inc. (1.42%). Insiders that own company stock include Christopher Brett Primiano, Deepika Pakianathan, Garen G Bohlin, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Michael Mano, Michael Mason, Reshma Rangwala, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener, Stuart Poulton and Tanya Lewis. View institutional ownership trends. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Karyopharm Therapeutics' stock price today? One share of KPTI stock can currently be purchased for approximately $1.27. How much money does Karyopharm Therapeutics make? Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $145.24 million and generates $157.07 million in revenue each year. The company earns $-165,290,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. How many employees does Karyopharm Therapeutics have? The company employs 385 workers across the globe. How can I contact Karyopharm Therapeutics? Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com. This page (NASDAQ:KPTI) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.